Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.680
+0.080 (5.00%)
Apr 8, 2026, 12:59 PM EDT - Market open
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 81 employees as of December 31, 2025. The number of employees decreased by 22 or -21.36% compared to the previous year.
Employees
81
Change (1Y)
-22
Growth (1Y)
-21.36%
Revenue / Employee
$614,852
Profits / Employee
-$621,494
Market Cap
711.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -22 | -21.36% |
| Dec 31, 2024 | 103 | -182 | -63.86% |
| Dec 31, 2023 | 285 | 150 | 111.11% |
| Dec 31, 2022 | 135 | 48 | 55.17% |
| Dec 31, 2021 | 87 | 9 | 11.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Replimune Group | 479 |
| Arvinas | 246 |
| Allogene Therapeutics | 152 |
| BridgeBio Oncology Therapeutics | 92 |
| Alto Neuroscience | 68 |
| Bright Minds Biosciences | 26 |
| Relmada Therapeutics | 17 |
LXRX News
- 15 days ago - Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo - GlobeNewsWire
- 16 days ago - Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 - GlobeNewsWire
- 4 weeks ago - Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates - GlobeNewsWire
- 5 weeks ago - Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences - GlobeNewsWire
- 5 weeks ago - Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 - GlobeNewsWire
- 2 months ago - Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire
- 2 months ago - Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire